We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.
Scancell
Redmile endorses technologies with a further £30mNexstim
Pilot studies lift off in depression and painAllergy Therapeutics
Strong performances against strategic goalsHutchison China MediTech
ESMO 2020: SANET-p delivers further positive suru dataMaxCyte
In the vanguard of next-generation cell and gene therapiesFutura Medical
MED3000 on course for OTC approval in Europe and USRedx Pharma
Proof is in the pipelineMereo BioPharma
TIGIT programme starts the next chapterScancell
UKRI awards funding for COVID-19 trialNexstim
Mapping out the 2020-24 corporate strategy